Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis.
<h4>Background</h4>COVID-19 vaccination is essential. However, no study has reported adverse events (AEs) after ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease (ESRD) on hemodialysis (HD). This study investigated the AEs within 30-days after the first dose of ChAdOx1...
Main Authors: | I-Ning Yang, Chin-Li Lu, Hung-Jen Tang, Yu-Chi Kuo, Li-Hwa Tsai, Kuan Chieh Tu, Jhi-Joung Wang, Chih-Chiang Chien |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0273676 |
Similar Items
-
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
by: I-Ning Yang, et al.
Published: (2022-01-01) -
Association of Reactogenicity with Immunogenicity of the ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Hemodialysis
by: Ting-Yun Lin, et al.
Published: (2022-08-01) -
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
by: Ogbe, A, et al.
Published: (2022) -
Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
by: Lea Krutzke, et al.
Published: (2022-07-01) -
LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
by: Tamara Garibashvili, et al.
Published: (2022-06-01)